Literature DB >> 17074566

Fine-needle aspiration biopsy of iris tumors in 100 consecutive cases: technique and complications.

Carol L Shields1, Maria E Manquez, Hormoz Ehya, Arman Mashayekhi, Carl J Danzig, Jerry A Shields.   

Abstract

OBJECTIVE: To evaluate the technique and complications of fine-needle aspiration biopsy (FNAB) for iris tumors.
DESIGN: Retrospective, nonrandomized, single-center case series. PARTICIPANTS: One hundred eyes of 100 patients with diagnostically challenging iris tumors evaluated with FNAB. MAIN OUTCOME MEASURES: Biopsy technique and complications.
RESULTS: Of more than 1400 patients referred with an iris tumor over a 24-year period, 100 underwent FNAB for diagnostic purposes. The median patient age was 44 years. The median basal dimension of the lesion was 9.0 mm and median thickness was 2.5 mm. A limbal entry with transaqueous approach parallel to the iris was used in 100% of patients. Entry was from the superotemporal (52%) or inferotemporal (42%) direction. Needle gauge size was 22 (9%), 25 (55%), 27 (25%), or 30 (9%), depending on the friability and vascularity of the tumor. Adequate tumor sample was achieved in 99 eyes (99%). At the time of FNAB, the only immediate complication was partial hyphema (34%). Two weeks after FNAB, persistent hyphema was found in 6 eyes (6%), requiring surgical washout in 1 patient. There were no cases of recurrent hyphema, vitreous hemorrhage, prolonged hypotony, lens damage, endophthalmitis, or extraocular tumor seeding. At mean follow-up of 5 years, there was no incident of tumor recurrence on the iris, along the needle tract, or on the corneal or epibulbar surface.
CONCLUSIONS: Using our technique, FNAB for diagnostically challenging iris tumors can achieve high yield with relatively few complications.

Entities:  

Mesh:

Year:  2006        PMID: 17074566     DOI: 10.1016/j.ophtha.2006.05.042

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  20 in total

Review 1.  Don't it make my blue eyes brown: heterochromia and other abnormalities of the iris.

Authors:  I G Rennie
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

Review 2.  A systematic review of cases reporting needle tract seeding following thyroid fine needle biopsy.

Authors:  Stergios A Polyzos; Athanasios D Anastasilakis
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

3.  Choroidal metastasis from hepatocellular carcinoma, diagnosed by fine needle aspiration biopsy and treated by iodine-125 brachytherapy.

Authors:  Lalkrushna Malaviya; Carol L Shields; Kiran Turaka; Hormoz Ehya; Jerry A Shields
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-02-09       Impact factor: 3.117

4.  Iris Melanoma in a Child Simulating Juvenile Xanthogranuloma.

Authors:  Jerry A Shields; Carol L Shields; Sara E Lally; Tatyana Milman; Ralph C Eagle
Journal:  Middle East Afr J Ophthalmol       Date:  2018 Apr-Jun

Review 5.  Uveal melanoma: relatively rare but deadly cancer.

Authors:  S Kaliki; C L Shields
Journal:  Eye (Lond)       Date:  2016-12-02       Impact factor: 3.775

6.  Exoresection via partial lamellar sclerouvectomy approach for uveal tumors: A successful performance by a novice surgeon.

Authors:  Rengin Aslihan Kurt; Kaan Gündüz
Journal:  Clin Ophthalmol       Date:  2010-02-02

7.  Exoresection and endoresection for uveal melanoma.

Authors:  Kaan Gündüz; Nikolaos E Bechrakis
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

8.  Fine needle aspiration biopsy of ophthalmic tumors.

Authors:  Arun D Singh; Charles V Biscotti
Journal:  Saudi J Ophthalmol       Date:  2012-04

9.  Vascularized solid iris lesion in a 3 year old child: 5 years of follow up.

Authors:  Antonio Maria Fea; Cristina Briamonte; Vittoria Aragno; Federico Maria Grignolo
Journal:  BMC Ophthalmol       Date:  2016-06-15       Impact factor: 2.209

10.  Diffuse Anterior Retinoblastoma with Sarcoidosis-Like Nodule.

Authors:  Koji Kitazawa; Kenji Nagata; Yukito Yamanaka; Yasumichi Kuwahara; Tomoko Iehara; Shigeru Kinoshita; Chie Sotozono
Journal:  Case Rep Ophthalmol       Date:  2015-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.